Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Pfizer Inc.

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
U.S. FDA Approves Pfizer’s CIBINQO® (abrocitinib) for Adults with Moderate-to-Severe Atopic Dermatitis
From Pfizer Inc.
Via Business Wire
Tickers PFE
Positive Top-Line Results of Pfizer’s Phase 3 Study Exploring Coadministration of PREVNAR 20™ With Pfizer-BioNTech COVID-19 Vaccine in Older Adults Released
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Enters into Agreement with Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in mRNA Vaccines and Therapeutics
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases
From Pfizer Inc.
Via Business Wire
Tickers BEAM PFE
Pfizer and BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
Pfizer to Provide U.S. Government with an Additional 10 Million Treatment Courses of its Oral Therapy to Help Combat COVID-19
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 12 Years of Age and Older
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Invites Public to View and Listen to Webcast of February 8 Conference Call with Analysts
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Receives U.S. FDA Emergency Use Authorization for Novel COVID-19 Oral Antiviral Treatment
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer to Provide the United Kingdom an Additional 2.5 Million Treatment Courses of Investigational Oral Antiviral Candidate to Help Combat COVID-19
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer’s VYNDAQEL®/VYNDAMAX® Reduced the Risk of All-Cause Mortality by 41% Among Patients with Transthyretin Amyloid Cardiomyopathy, Five-Year Follow-Up Data Demonstrate
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer and BioNTech to Provide European Union More Than 200 Million Additional Doses of COMIRNATY® to Help Meet Continued Need for Vaccine Supply
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
EMA Issues Advice for Potential Early Use of Pfizer’s Novel COVID-19 Oral Antiviral Candidate
From Pfizer Inc.
Via Business Wire
Tickers PFE
U.S. FDA Approves Pfizer’s XELJANZ® (tofacitinib) for the Treatment of Active Ankylosing Spondylitis
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Announces Additional Phase 2/3 Study Results Confirming Robust Efficacy of Novel COVID-19 Oral Antiviral Treatment Candidate in Reducing Risk of Hospitalization or Death
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer to Acquire Arena Pharmaceuticals
From Pfizer Inc.
Via Business Wire
Tickers ARNA PFE
Pfizer Declares First-Quarter 2022 Dividend
From Pfizer Inc.
Via Business Wire
Tickers PFE
European Commission Approves Pfizer’s Cibinqo® (abrocitinib) for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 16 Years and Older
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
Pfizer and BioNTech Provide Update on Omicron Variant
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
Pfizer Invites Public to Register for Webcast of Analyst and Investor Call to Discuss Pfizer-BioNTech COVID-19 Vaccine and Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Tickers PFE
Follow-Up Data From Phase 3 Trial of Pfizer-BioNTech COVID-19 Vaccine Support Safety and High Efficacy in Adolescents 12 Through 15 Years of Age
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
Pfizer and BioNTech Receive Expanded U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster to Include Individuals 18 and Older
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
Pfizer’s XELJANZ® (tofacitinib) Receives Marketing Authorization in the European Union for the Treatment of Active Ankylosing Spondylitis
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer to Provide U.S. Government with 10 Million Treatment Courses of Investigational Oral Antiviral Candidate to Help Combat COVID-19
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Completes Acquisition of Trillium Therapeutics
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Announces Retirement of Chief Financial Officer Frank D’Amelio
From Pfizer Inc.
Via Business Wire
Tickers PFE
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.